Patents in terms of relationship between phenotype and genotype.
sole application by StaGen |
|
|---|---|
| Patent No. | Registration No.3656952 (Japan) |
| Project Name | ＳＡＡ１／Amyloidosis |
| Title | Method for Detecting Morbidity Risk of AA-Amyloidosis in Rheumatoid Arthritis Patient by Detecting a New SNP in SAA1 Genetic Locus |
| Abstract | To provide a method capable of detecting morbidity risk of AA-amyloidosis in rheumatoid arthritis using new oligonucleotides probes in the method. SOLUTION: In this method for the detecting SAA1 (serum amyloid A1 protein) gene, the morbidity risk of AA-amyloidosis in rheumatoid arthritis, it is determined whether a base at the -13 of human SAA1 gene is thymine or cytosine. The DNA contains a base sequence GCCACCGTTC CCTGG or a base sequence GCCACCGCTC CCTGG. |
| Working example | DNA chip etc. |
| Information | 1. Moriguchi M, Terai C, Kaneko H, Koseki Y, Kajiyama H, Uesato M, Inada S, Kamatani N. A novel single-nucleotide polymorphism at the 5'-flanking region of SAA1 associated with risk of type AA amyloidosis secondary to rheumatoid arthritis. Arthritis Rheum. 2001;44(6):1266-72. 2. Moriguchi M, Kaneko H, Terai C, Koseki Y, Kajiyama H, Inada S, Kitamura Y, Kamatani N. Relative transcriptional activities of SAA1 promoters polymorphic at position -13(T/C): potential association between increased transcription and amyloidosis. Amyloid. 2005 ;12(1):26-32. |
sole application by StaGen |
|
|---|---|
| Patent No. | Registration No.3675803 (Japan) US2004265816 WO03004638 (USA) |
| Project Name | NAT2 |
| Title | Method for evaluating the Risk of Adverse Effects of Therapeutic Agents for Rheumatoid Arthritis (RA) |
| Abstract | The correlation between the diplotype configuration of the NAT2 gene and the adverse effect of SASP (Salicylazosulfapyridine) in RA patients was assessed. It was discovered that the incidence rate of adverse effects was higher in the patients having no wild type haplotype who were treated with SASP. Thus, the risk of adverse effects of SASP for each individual can be evaluated by determining the diplotype configuration at the NAT2 gene for each subject in terms of the presence of the wild type haplotype |
| Working example | DNA chip etc. |
| Information | 1. Tanaka E, Taniguchi A, Urano W, Nakajima H, Matsuda Y, Kitamura Y, Saito M,Yamanaka H, Saito T, Kamatani N. Adverse effects of sulfasalazine in patients with rheumatoid arthritis are associated with diplotype configuration at the N-acetyltransferase 2 gene. J Rheumatol. 2002;29(12):2492-9. |
sole application by StaGen |
|
|---|---|
| Patent No. | JP 2003-292537（Japan) |
| Project Name | Calpain 10 |
| Title | Method to estimate the risk of type 2 diabetes using genomic variations in calpain 10 gene. |
| Abstract | Estimate the risk of type 2 diabetes especially for Japanese by the SNP analysis, and based on the estimation, prevention of the disease becomes more efficient. |
| Working example | DNA chip etc. |
| Information | Iwasaki N, Horikawa Y, Tsuchiya T, Kitamura Y, Nakamura T, Tanizawa Y, Oka Y, Hara K, Kadowaki T, Awata T, Honda M, Yamashita K, Oda N, Yu L, Yamada N, Ogata M, Kamatani N, Iwamoto Y, Del Bosque-Plata L, Hayes MG, Cox NJ, Bell GI. Genetic variants in the calpain-10 gene and the development of type 2 diabetesin the Japanese population. J Hum Genet. 2005;50(2):92-8. |
sole application by StaGen |
|
|---|---|
| Patent No. | JP 2005-172045（Japan) |
| Project Name | ＶＥＧＦ |
| Title | Method to estimate the risks of development and progression of diabetic retinopathy |
| Abstract | By the analysis of SNP in VEGF gene, the risk of development and progression of diabetic retinopathy can be estimated, and, based on the risk, the prevention of the retinopathy becomes more efficient |
| Working example | DNA chip etc. |
| Information | |
sole application by StaGen |
|
|---|---|
| Patent No. | Registration No.3839836 (Japan) |
| Project Name | ＭＴＸ |
| Title | Method to administer methotrexate (MTX) |
| Abstract | Method to estimate the effective dose of MTX for the treatment of rheumatoid arthritis. The individual effective dose of MTX can be estimated by the analysis of a SNP in MTHFR gene. |
| Working example | DNA chip etc. |
| Information | 1. Taniguchi A, Kamatani N. Pharmacogenetic approaches to rheumatoid arthritis.Pharmacogenomics J. 2004;4(6):350-3. 2. Taniguchi A, Urano W, Tanaka E, Furihata S, Kamitsuji S, Inoue E, Yamanaka M, Yamanaka H, Kamatani N. Validation of the associations between SNPs or haplotypes and responses to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a proposal for prospective pharmacogenomic study in clinical practice. Pharmacogenetics Genomics in press. 3. Urano W, Taniguchi A, Yamanaka H, Tanaka E, Nakajima H, Matsuda Y, Akama H, Kitamura Y, Kamatani N. Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses. Pharmacogenetics. 12:183-190, 2002. 4. Taniguchi A, Urano W, Tanaka E, Furihata S, Kamitsuji S, Inoue E, Yamanaka M, Yamanaka H, Kamatani N. Validation of the associations between SNPs or haplotypes and responses to disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: a proposal for prospective pharmacogenomic study in clinical practice. Pharmacogenetics and Genomics. 2007;17(6):383-390. |